866-997-4948(US-Canada Toll Free)

PharmaPoint: Obesity - Japan Drug Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Oct 2013

Category :

Metabolic Disorders

No. of Pages : 83 Pages

PharmaPoint: Obesity - Japan Drug Forecast and Market Analysis to 2022

Summary

After a more than decade long dormancy, the Obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple pathways and regulate appetite control, as well as novel molecular entities with new mechanisms of action. Due to this growing pipeline of late-stage drugs, this market is expected to experience substantial growth over the next decade.

Until the late 1990s, Japans pharmaceutical market structure differed greatly from that of the rest of the world, particularly western countries. The drug approval process was very slow and gave preference to domestic producers. Regulators and physicians were highly risk-averse, and the NHI system insulated manufacturers from the demands of the market. These factors combined to create an uncompetitive industry and subpar products.

Scope

- Overview of Obesity including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Obesity market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Obesity.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2012-2022 in Japan.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 15
3.1.1 Etiology 15
3.1.2 Pathophysiology 16
3.1.3 Prognosis 16
3.1.4 Quality of Life 17
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 18
4.2 Japan 23
4.2.1 Diagnosis 23
4.2.2 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 30
5.3 Product Profiles: Drugs 32
5.3.1 Oblean (cetilistat) 32
6 Opportunity and Unmet Need 35
6.1 Overview 35
6.2 A Drug with Greater Than 10% Average Weight Loss 36
6.2.1 Unmet Need 36
6.2.2 Gap Analysis 37
6.2.3 Opportunity 38
6.3 A Drug with Increased Safety and Tolerability 38
6.3.1 Unmet Need 38
6.3.2 Gap Analysis 39
6.3.3 Opportunity 39
6.4 Reimbursement by Private and Public Payers 39
6.4.1 Unmet Need 39
6.4.2 Gap Analysis 41
6.4.3 Opportunity 41
6.5 Increased Physician Education 41
6.5.1 Unmet Need 41
6.5.2 Gap Analysis 42
6.5.3 Opportunity 42
6.6 Increased Drug-Treatment Rate 43
6.6.1 Unmet Need 43
6.6.2 Gap Analysis 43
6.6.3 Opportunity 44
6.7 Improved Guidelines 44
6.7.1 Unmet Need 44
6.7.2 Gap Analysis 45
6.7.3 Opportunity 45
6.8 Improved Approach to Diagnosis 45
6.8.1 Unmet Need 45
6.8.2 Gap Analysis 46
6.8.3 Opportunity 46
7 Pipeline Assessment 47
7.1 Overview 47
7.2 Promising Drugs in Clinical Development 50
7.2.1 Velneperit 53
8 Market Outlook 57
8.1 Japan 58
8.1.1 Forecast 58
8.1.2 Key Events 61
8.1.3 Drivers and Barriers 61
9 Appendix 63
9.1 Bibliography 63
9.2 Abbreviations 70
9.3 Research Methodology 72
9.4 Forecasting Methodology 72
9.4.1 Percent Drug-Treated Obesity Patients 73
9.4.2 Drugs Included in Each Therapeutic Class 73
9.4.3 Launch and Patent Expiry Dates 74
9.4.4 General Pricing Assumptions 74
9.4.5 Individual Drug Assumptions 75
9.4.6 Generic Erosion 75
9.4.7 Pricing of Pipeline Agents 75
9.5 Physicians, Specialists, and Payers Included in This Study 76
9.6 About the Authors 79
9.6.1 Analysts 79
9.6.2 Therapy Director - CVMD and Infectious Disease 80
9.6.3 Director - Medical Devices 80
9.6.4 Global Head of Healthcare 81
9.7 About GlobalData 82
9.8 Disclaimer 82

List of Table

1.1 List of Tables
Table 1: Target Pathways in the Treatment of Obesity 16
Table 2: Symptoms of Obesity 17
Table 3: Treatment Guidelines for Obesity 21
Table 4: Most Prescribed Drugs for Obesity by Class in the Global Markets, 2013 22
Table 5: Classification of Overweight and Obesity by BMI and Waist Circumference, and the Associated Disease Risk 23
Table 6: Bariatric Treatment Attributes 29
Table 7: Leading Drug Treatments for Obesity, 2013 30
Table 8: Marketed Obesity Treatment Devices by Type 31
Table 9: Product Profile - Oblean 33
Table 10: ObleanSWOT Analysis, 2013 34
Table 11: Unmet Need and Opportunity in Obesity 36
Table 12: Endpoint Analysis of Clinical Trials Conducted in Obesity, 2013 49
Table 13: Obesity - Phase II-III Pipeline, 2013 50
Table 14: Comparison of Therapeutic Classes in Development for Obesity, 2013 52
Table 15: Obesity Treatment Pipeline Devices by Type 52
Table 16: Product Profile - Velneperit 53
Table 17: Velneperit SWOT Analysis, 2013 56
Table 18: Sales Forecasts ($) for Obesity in Japan, 2012-2022 59
Table 19: Events Impacting Sales for Obesity in Japan, 2012-2022 61
Table 20: Obesity Market in Japan - Drivers and Barriers, 2012-2022 61
Table 21: Key Launch Dates 74
Table 22: Key Patent Expiries 74

List of Chart

1.2 List of Figures
Figure 1: Treatment Algorithm for Obesity 20
Figure 2: Projected Increase in the Pharmacological Treatment of Overweight and Obese Patients in Japan, 2012-2022 24
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Obesity, 2012-2022 51
Figure 4: Sales for Obesity in Japan by Drug Class, 2012-2022 60

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *